Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity

[1]  S. Grimm,et al.  Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration. , 2022, Journal of psychiatric research.

[2]  A. Khullar,et al.  Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing , 2022, CNS Drugs.

[3]  E. Lenze,et al.  Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence , 2022, Journal of the Neurological Sciences.

[4]  A. Gardier,et al.  CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity , 2021, Neuropharmacology.

[5]  D. Carson,et al.  Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations , 2021, Translational Psychiatry.

[6]  A. Kwan,et al.  Ketamine for a Boost of Neural Plasticity: How, but Also When? , 2021, Biological Psychiatry.

[7]  Li-ming Zhang,et al.  The role of the excitation:inhibition functional balance in the mPFC in the onset of antidepressants , 2021, Neuropharmacology.

[8]  Y. Kozorovitskiy,et al.  Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms , 2021, Biological Psychiatry.

[9]  R. Liu,et al.  Ketamine activated glutamatergic neurotransmission by GABAergic disinhibition in the medial prefrontal cortex , 2020, Neuropharmacology.

[10]  W. Lasoń,et al.  Developments in the discovery and design of intranasal antidepressants , 2020, Expert opinion on drug discovery.

[11]  R. Hen,et al.  Rapid Anxiolytic Effects of RS67333, a Serotonin Type 4 Receptor Agonist, and Diazepam, a Benzodiazepine, Are Mediated by Projections From the Prefrontal Cortex to the Dorsal Raphe Nucleus , 2020, Biological Psychiatry.

[12]  D. David,et al.  Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine , 2020, Pharmacology Biochemistry and Behavior.

[13]  K. Sim,et al.  Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. , 2020, Journal of affective disorders.

[14]  R. Duman,et al.  Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents , 2019, Neurobiology of Disease.

[15]  Elisabeth Mahase.  Esketamine is approved in Europe for treating resistant major depressive disorder , 2019, BMJ.

[16]  T. Davis,et al.  Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration , 2019, Pharmaceutics.

[17]  E. Turner,et al.  Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. , 2019, The lancet. Psychiatry.

[18]  Xiang Li,et al.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.

[19]  Yuko Fujita,et al.  MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling , 2019, Psychopharmacology.

[20]  Yuko Fujita,et al.  Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine , 2019, Pharmacology Biochemistry and Behavior.

[21]  T. Govender,et al.  Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion. , 2019, Journal of psychiatric research.

[22]  Mitchell H. Murdock,et al.  Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation , 2019, Science.

[23]  T. Gould,et al.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms , 2018, Pharmacological Reviews.

[24]  W. Drevets,et al.  Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. , 2018, The American journal of psychiatry.

[25]  A. Gardier,et al.  Rapid analysis of glutamate, glutamine and GABA in mice frontal cortex microdialysis samples using HPLC coupled to electrospray tandem mass spectrometry , 2018, Journal of pharmaceutical and biomedical analysis.

[26]  L. McMahon,et al.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy , 2018, Proceedings of the National Academy of Sciences.

[27]  R. Shelton,et al.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial , 2017, JAMA psychiatry.

[28]  C. Denny,et al.  Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine–Induced Sustained Antidepressant-like Effects , 2017, Biological Psychiatry.

[29]  Etienne Sibille,et al.  Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives , 2017, Biological Psychiatry.

[30]  Timothy H Murphy,et al.  Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine , 2017, Brain : a journal of neurology.

[31]  C. Liston,et al.  Cortex-wide optical imaging and network analysis of antidepressant effects. , 2017, Brain : a journal of neurology.

[32]  A. Maffei,et al.  Neurophysiology and Regulation of the Balance Between Excitation and Inhibition in Neocortical Circuits , 2017, Biological Psychiatry.

[33]  Allison C. Nugent,et al.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine , 2017, Biological Psychiatry.

[34]  M. Joëls,et al.  Forebrain glutamatergic, but not GABAergic, neurons mediate anxiogenic effects of the glucocorticoid receptor , 2017, Molecular Psychiatry.

[35]  D. David,et al.  Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice , 2017, Neuropharmacology.

[36]  N. Just,et al.  Investigating the Role of Glutamate and GABA in the Modulation of Transthalamic Activity: A Combined fMRI-fMRS Study , 2017, Front. Physiol..

[37]  T. Fuchs,et al.  Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state , 2016, Molecular Psychiatry.

[38]  Phillip E. Vlisides,et al.  Ketamine: 50 Years of Modulating the Mind , 2016, Front. Hum. Neurosci..

[39]  D. Frost,et al.  Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[40]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[41]  D. Stellwagen,et al.  Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment , 2016, Biological Psychiatry.

[42]  E. Gillam,et al.  Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs , 2016, Drug metabolism reviews.

[43]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[44]  Oliver H. Miller,et al.  Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition , 2016, Neuropharmacology.

[45]  O. Andreassen,et al.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders , 2016, Molecular Psychiatry.

[46]  D. Charney,et al.  A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder , 2014, Biological Psychiatry.

[47]  M. Galloway,et al.  Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: An 11.7T 1H-MRS study in rats , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[48]  R. Hen,et al.  Rapid Anxiolytic Effects of a 5-HT4 Receptor Agonist Are Mediated by a Neurogenesis-Independent Mechanism , 2014, Neuropsychopharmacology.

[49]  R. Hen,et al.  A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: β-arrestin 1 protein levels in depression and treatment , 2013, Front. Pharmacol..

[50]  S. Chaki,et al.  Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats , 2013, Pharmacology Biochemistry and Behavior.

[51]  Sharon Miksys,et al.  Cytochrome P450-mediated drug metabolism in the brain. , 2013, Journal of psychiatry & neuroscience : JPN.

[52]  J. Stern,et al.  Astrocytes Modulate a Postsynaptic NMDA–GABAA-Receptor Crosstalk in Hypothalamic Neurosecretory Neurons , 2013, The Journal of Neuroscience.

[53]  C. Sánchez,et al.  Blockade of the high‐affinity noradrenaline transporter (NET) by the selective 5‐HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice , 2013, British journal of pharmacology.

[54]  Zhi-qiang Zhou,et al.  Tramadol reinforces antidepressant effects of ketamine with increased levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in rat hippocampus , 2012, Frontiers of Medicine.

[55]  G. Aghajanian,et al.  Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex , 2012, Biological Psychiatry.

[56]  R. Thorne,et al.  Intranasal delivery of biologics to the central nervous system. , 2012, Advanced drug delivery reviews.

[57]  D. David,et al.  Functional Status of Somatodendritic Serotonin 1A Autoreceptor after Long-Term Treatment with Fluoxetine in a Mouse Model of Anxiety/Depression Based on Repeated Corticosterone Administration , 2012, Molecular Pharmacology.

[58]  J. Alvarez,et al.  An automated method for measurement of methoxetamine in human plasma by use of turbulent flow on-line extraction coupled with liquid chromatography and mass spectrometric detection , 2012, Analytical and Bioanalytical Chemistry.

[59]  C. Klaassen,et al.  Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[60]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[61]  G. Réus,et al.  Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain , 2011, Behavioural Brain Research.

[62]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[63]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[64]  L. Mucke,et al.  Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. , 2009, Cell stem cell.

[65]  M. Drew,et al.  Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression , 2009, Neuron.

[66]  R. Hen,et al.  Behavioral Effects of Chronic Fluoxetine in BALB/cJ Mice Do Not Require Adult Hippocampal Neurogenesis or the Serotonin 1A Receptor , 2008, Neuropsychopharmacology.

[67]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[68]  Richard S. Ehrlichman,et al.  Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli , 2006, Journal of Pharmacology and Experimental Therapeutics.

[69]  P. Lestage,et al.  Rapid and precise method to locate microdialysis probe implantation in the rodent brain , 2004, Journal of Neuroscience Methods.

[70]  Brigitta B. Gundersen,et al.  Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression , 2004, Neuropsychopharmacology.

[71]  C. Belzung,et al.  Behaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice , 2004, Physiology & Behavior.

[72]  G F Mason,et al.  Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments , 2002, Molecular Psychiatry.

[73]  J. Gustafsson,et al.  Cytochrome P450 in the brain; a review. , 2001, Current drug metabolism.

[74]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[75]  Fahmeed Hyder,et al.  Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy , 1999 .

[76]  M. Detke,et al.  Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test , 1999, Psychopharmacology.

[77]  F. Servin,et al.  Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. , 1996, British journal of anaesthesia.

[78]  R. Porsolt,et al.  Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.